BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...involve E3 ligases or the proteasome at all.Lycia Therapeutics Inc....
...Tuzman Arvinas Inc. Kymera Therapeutics Inc. C4 Therapeutics Inc. Nurix Therapeutics Inc. Lycia Therapeutics Inc. PolyProx...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

...companies in the protein degradation space, which tag intracellular targets for destruction by the proteasome, Lycia Therapeutics Inc....
...to comment on the study, and Crews did not return requests for comment. COMPANY PROFILE Lycia Therapeutics Inc....
...PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Karen Tkach Tuzman, Associate Editor Targeted degradation LYTACs Carolyn Bertozzi Lycia Therapeutics Inc....
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

...extracellular proteins and large aggregates and organelles, respectively. Last year, Stanford Professor Carolyn Bertozzi founded Lycia Therapeutics Inc....
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

...gain of function,” said Stanford University professor Carolyn Bertozzi. Bertozzi is the scientific founder of Lycia Therapeutics Inc....
Items per page:
1 - 4 of 4
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...involve E3 ligases or the proteasome at all.Lycia Therapeutics Inc....
...Tuzman Arvinas Inc. Kymera Therapeutics Inc. C4 Therapeutics Inc. Nurix Therapeutics Inc. Lycia Therapeutics Inc. PolyProx...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

...companies in the protein degradation space, which tag intracellular targets for destruction by the proteasome, Lycia Therapeutics Inc....
...to comment on the study, and Crews did not return requests for comment. COMPANY PROFILE Lycia Therapeutics Inc....
...PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 Karen Tkach Tuzman, Associate Editor Targeted degradation LYTACs Carolyn Bertozzi Lycia Therapeutics Inc....
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

...extracellular proteins and large aggregates and organelles, respectively. Last year, Stanford Professor Carolyn Bertozzi founded Lycia Therapeutics Inc....
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

...gain of function,” said Stanford University professor Carolyn Bertozzi. Bertozzi is the scientific founder of Lycia Therapeutics Inc....
Items per page:
1 - 4 of 4